32 results on '"Christopher J. Farady"'
Search Results
2. Evaluation of protein kinase D auto-phosphorylation as biomarker for NLRP3 inflammasome activation
- Author
-
Diane Heiser, Joëlle Rubert, Adeline Unterreiner, Claudine Maurer, Marion Kamke, Ursula Bodendorf, Christopher J. Farady, Ben Roediger, and Frédéric Bornancin
- Subjects
Medicine ,Science - Abstract
Background The NLRP3 inflammasome is a critical component of sterile inflammation, which is involved in many diseases. However, there is currently no known proximal biomarker for measuring NLRP3 activation in pathological conditions. Protein kinase D (PKD) has emerged as an important NLRP3 kinase that catalyzes the release of a phosphorylated NLRP3 species that is competent for inflammasome complex assembly. Methods To explore the potential for PKD activation to serve as a selective biomarker of the NLRP3 pathway, we tested various stimulatory conditions in THP-1 and U937 cell lines, probing the inflammasome space beyond NLRP3. We analyzed the correlation between PKD activation (monitored by its auto-phosphorylation) and functional inflammasome readouts. Results PKD activation/auto-phosphorylation always preceded cleavage of caspase-1 and gasdermin D, and treatment with the PKD inhibitor CRT0066101 could block NLRP3 inflammasome assembly and interleukin-1β production. Conversely, blocking NLRP3 either genetically or using the MCC950 inhibitor prevented PKD auto-phosphorylation, indicating a bidirectional functional crosstalk between NLRP3 and PKD. Further assessments of the pyrin and NLRC4 pathways, however, revealed that PKD auto-phosphorylation can be triggered by a broad range of stimuli unrelated to NLRP3 inflammasome assembly. Conclusion Although PKD and NLRP3 become functionally interconnected during NLRP3 activation, the promiscuous reactivity of PKD challenges its potential use for tracing the NLRP3 inflammasome pathway.
- Published
- 2021
3. IL-1β promotes MPN disease initiation by favoring early clonal expansion ofJAK2-mutant hematopoietic stem cells
- Author
-
Shivam Rai, Yang Zhang, Elodie Grockowiak, Quentin Kimmerlin, Nils Hansen, Cedric B. Stoll, Marc Usart, Hui Hao-Shen, Michael S. Bader, Jakob R. Passweg, Stefan Dirnhofer, Christopher J. Farady, Timm Schroeder, Simón Méndez-Ferrer, and Radek C. Skoda
- Abstract
JAK2-V617F is the most frequent somatic mutation causing myeloproliferative neoplasm (MPN). However,JAK2-V617F can also be found in healthy individuals with clonal hematopoiesis of indeterminate potential (CHIP) with a frequency much higher than the prevalence of MPN. The factors controlling the conversion ofJAK2-V617F CHIP to MPN are largely unknown. We hypothesized that IL-1β mediated inflammation is one of the factors that favors this progression. We examined mono- or oligoclonal evolution of MPN by performing bone marrow transplantations at limiting dilutions with only 1-3JAK2-mutant HSCs per recipient. Genetic loss ofIL-1βinJAK2-mutant hematopoietic cells or inhibition by a neutralizing anti-IL-1β antibody restricted the early clonal expansion of theseJAK2-mutant HSCs resulting in a reduced frequency of a CHIP-like state and a lower rate of conversion to MPN. The MPN disease-promoting effects of IL-1β were associated with damage to sympathetic innervation leading to loss of nestin-positive mesenchymal stromal cells and required the presence ofIL-1R1on bone marrow stromal cells. The anti-IL-1β antibody protected these mesenchymal stromal cells from IL-1β mediated damage and limited the expansion of theJAK2-mutant clone. Our results identify IL-1β as a potential therapeutic target for preventing the transition fromJAK2-V617F CHIP to MPN.Brief summaryIn a mouse model of oligo-clonal myeloproliferative neoplasm (MPN), IL-1β produced byJAK2-mutant cells favored expansion of sub-clinicalJAK2-V617F clones and initiation of MPN disease.
- Published
- 2023
4. Supplementary Figure 4 from Tumor Detection by Imaging Proteolytic Activity
- Author
-
Charles S. Craik, Byron C. Hann, James D. Marks, Christopher J. Farady, Paul J. Phojanakong, Jianlong Lou, Eric L. Schneider, and Molly R. Darragh
- Abstract
Supplementary Figure 4 from Tumor Detection by Imaging Proteolytic Activity
- Published
- 2023
5. Supplementary Figure 2 from Tumor Detection by Imaging Proteolytic Activity
- Author
-
Charles S. Craik, Byron C. Hann, James D. Marks, Christopher J. Farady, Paul J. Phojanakong, Jianlong Lou, Eric L. Schneider, and Molly R. Darragh
- Abstract
Supplementary Figure 2 from Tumor Detection by Imaging Proteolytic Activity
- Published
- 2023
6. Supplementary Figure 1 from Tumor Detection by Imaging Proteolytic Activity
- Author
-
Charles S. Craik, Byron C. Hann, James D. Marks, Christopher J. Farady, Paul J. Phojanakong, Jianlong Lou, Eric L. Schneider, and Molly R. Darragh
- Abstract
Supplementary Figure 1 from Tumor Detection by Imaging Proteolytic Activity
- Published
- 2023
7. Data from Tumor Detection by Imaging Proteolytic Activity
- Author
-
Charles S. Craik, Byron C. Hann, James D. Marks, Christopher J. Farady, Paul J. Phojanakong, Jianlong Lou, Eric L. Schneider, and Molly R. Darragh
- Abstract
The cell surface protease membrane-type serine protease-1 (MT-SP1), also known as matriptase, is often upregulated in epithelial cancers. We hypothesized that dysregulation of MT-SP1 with regard to its cognate inhibitor hepatocyte growth factor activator inhibitor-1 (HAI-1), a situation that increases proteolytic activity, might be exploited for imaging purposes to differentiate malignant from normal tissue. In this study, we show that MT-SP1 is active on cancer cells and that its activity may be targeted in vivo for tumor detection. A proteolytic activity assay with several MT-SP1–positive human cancer cell lines showed that MT-SP1 antibodies that inhibit recombinant enzyme activity in vitro also bind and inhibit the full-length enzyme expressed on cells. In contrast, in the same assay, MT-SP1–negative cancer cell lines were inactive. Fluorescence microscopy confirmed the cell surface localization of labeled antibodies bound to MT-SP1–positive cells. To evaluate in vivo targeting capability, 0.7 to 2 nmoles of fluorescently labeled antibodies were administered to mice bearing tumors that were positive or negative for MT-SP1. Antibodies localized to MT-SP1–positive tumors (n = 3), permitting visualization of MT-SP1 activity, whereas MT-SP1–negative tumors (n = 2) were not visualized. Our findings define MT-SP1 activity as a useful biomarker to visualize epithelial cancers using a noninvasive antibody-based method. Cancer Res; 70(4); 1505–12
- Published
- 2023
8. Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis
- Author
-
Emilia Neuwirt, Giovanni Magnani, Tamara Ćiković, Svenja Wöhrle, Larissa Fischer, Anna Kostina, Stephan Flemming, Nora J. Fischenich, Benedikt S. Saller, Oliver Gorka, Steffen Renner, Claudia Agarinis, Christian N. Parker, Andreas Boettcher, Christopher J. Farady, Rebecca Kesselring, Christopher Berlin, Rolf Backofen, Marta Rodriguez-Franco, Clemens Kreutz, Marco Prinz, Martina Tholen, Thomas Reinheckel, Thomas Ott, Christina J. Groß, Philipp J. Jost, and Olaf Groß
- Subjects
Cell Biology ,Molecular Biology ,Biochemistry - Abstract
Inflammasomes are intracellular protein complexes that promote an inflammatory host defense in response to pathogens and damaged or neoplastic tissues and are implicated in inflammatory disorders and therapeutic-induced toxicity. We investigated the mechanisms of activation for inflammasomes nucleated by NOD-like receptor (NLR) proteins. A screen of a small-molecule library revealed that several tyrosine kinase inhibitors (TKIs)—including those that are clinically approved (such as imatinib and crizotinib) or are in clinical trials (such as masitinib)—activated the NLRP3 inflammasome. Furthermore, imatinib and masitinib caused lysosomal swelling and damage independently of their kinase target, leading to cathepsin-mediated destabilization of myeloid cell membranes and, ultimately, cell lysis that was accompanied by potassium (K + ) efflux, which activated NLRP3. This effect was specific to primary myeloid cells (such as peripheral blood mononuclear cells and mouse bone marrow–derived dendritic cells) and did not occur in other primary cell types or various cell lines. TKI-induced lytic cell death and NLRP3 activation, but not lysosomal damage, were prevented by stabilizing cell membranes. Our findings reveal a potential immunological off-target of some TKIs that may contribute to their clinical efficacy or to their adverse effects.
- Published
- 2023
9. Pharmacological inhibition of IKKβ dampens NLRP3 inflammasome activation after priming in the human myeloid cell line THP-1
- Author
-
Andreas Boettcher, Adeline Unterreiner, Muriel Kauffmann, Christopher J. Farady, Jörg Eder, Alice Fruhauf, Ursula Bodendorf, Joëlle Rubert, Diane Heiser, Achim Schlapbach, Frédéric Bornancin, and P. Erbel
- Subjects
0301 basic medicine ,Inflammasomes ,THP-1 Cells ,Interleukin-1beta ,Biophysics ,Caspase 1 ,Priming (immunology) ,Thiophenes ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,NLR Family, Pyrin Domain-Containing 3 Protein ,medicine ,Humans ,THP1 cell line ,Secretion ,Protein Kinase Inhibitors ,Molecular Biology ,Innate immune system ,integumentary system ,Chemistry ,Kinase ,NF-kappa B ,Inflammasome ,Cell Biology ,Amides ,Immunity, Innate ,I-kappa B Kinase ,Cell biology ,030104 developmental biology ,Nigericin ,030220 oncology & carcinogenesis ,NLRP3 inflammasome complex ,medicine.drug - Abstract
The NLRP3 inflammasome is a critical component of the innate immune response to sterile inflammation. Its regulation involves a priming step, required for up-regulation of inflammasome protagonists and an activation step leading to NLRP3 inflammasome complex assembly, which triggers caspase-1 activity. The IκKβ kinase regulates canonical NF-κB, a key pathway involved in transcriptional priming. We found that IκKβ also regulates the activation and function of the NLRP3 inflammasome beyond the priming step. Two unrelated IκKβ inhibitors, AFN700 and TPCA-1, when applied after priming, fully blocked IL-1β secretion triggered by nigericin in THP-1 cells. Both inhibitors prevented neither inflammasome assembly, as monitored by measuring the formation of ASC specks, nor the generation of caspase-1 p20, a hallmark of caspase-1 activity, but they impaired the initial cleavage and activation of procaspase-1. These data thus indicate that IκKβ activity is required for efficient activation of NLRP3, suggesting that IκKβ may fulfill a dual role in coupling priming and activation of the NLRP3 inflammasome.
- Published
- 2021
10. Tyrosine kinase inhibitors trigger lysosomal damage-associated cell lysis to activate the NLRP3 inflammasome
- Author
-
Emilia Neuwirt, Giovanni Magnani, Tamara Ćiković, Anna Kostina, Svenja Wöhrle, Stephan Flemming, Larissa Fischer, Nora J. Fischenich, Benedikt S. Saller, Oliver Gorka, Steffen Renner, Claudia Agarinis, Christian Parker, Andreas Boettcher, Christopher J. Farady, Rolf Backofen, Marta Rodriguez-Franco, Martina Tholen, Thomas Reinheckel, Thomas Ott, Christina J. Groß, Philipp J. Jost, and Olaf Groß
- Abstract
Inflammasomes are intracellular protein complexes that control proteolytic maturation and secretion of inflammatory interleukin-1 (IL-1) family cytokines and are thus important in host defense. While some inflammasomes are activated simply by binding to pathogen-derived molecules, others, including those nucleated by NLRP3 and NLRP1, have more complex activation mechanisms that are not fully understood. We screened a library of small molecules to identify new inflammasome activators that might shed light on activation mechanisms. In addition to validating dipeptidyl peptidase (DPP) inhibitors as NLRP1 activators, we find that clinical tyrosine kinase inhibitors (TKIs) including imatinib and masitinib activate the NLRP3 inflammasome. Mechanistically, these TKIs cause lysosomal swelling and damage, leading to cathepsin-mediated destabilization of myeloid cell membranes and cell lysis. This is accompanied by potassium (K+) efflux, which activates NLRP3. Both lytic cell death and NLRP3 activation but not lysosomal damage induced by TKIs are prevented by the cytoprotectant high molecular weight polyethylene glycol (PEG). Our study establishes a screening method that can be expanded for inflammasome research and immunostimulatory drug development, and provides new insight into immunological off-targets that may contribute to efficacy or adverse effects of TKIs.One Sentence SummaryA functional small molecule screen identifies imatinib, masitinib and other tyrosine kinase inhibitors that destabilize myeloid cell lysosomes, leading to cell lysis and K+ efflux-dependent NLRP3 inflammasome activation.
- Published
- 2022
11. Crystal Structure of NLRP3 NACHT Domain With an Inhibitor Defines Mechanism of Inflammasome Inhibition
- Author
-
Andreas Boettcher, Alexandra Hinniger, Christopher J. Farady, Sandra Kapps-Fouthier, Nicola Hughes, Henri Mattes, Carien Dekker, Jörg Eder, Angela Mackay, Nikolaus Stiefl, Michael Wright, and P. Erbel
- Subjects
Sulfonamides ,Innate immune system ,Binding Sites ,integumentary system ,Mechanism (biology) ,Chemistry ,Inflammasomes ,Binding pocket ,Inflammasome ,Crystal structure ,Crystallography, X-Ray ,Cell biology ,Gain of function ,Indenes ,Protein Domains ,Structural Biology ,Catalytic Domain ,NACHT domain ,NLR Family, Pyrin Domain-Containing 3 Protein ,medicine ,Humans ,Furans ,Molecular Biology ,medicine.drug - Abstract
The NLRP3 inflammasome assembles in response to a variety of pathogenic and sterile danger signals, resulting in the production of interleukin-1β and interleukin-18. NLRP3 is a key component of the innate immune system and has been implicated as a driver of a number of acute and chronic diseases. We report the 2.8 A crystal structure of the NLRP3 NACHT domain in complex with an inhibitor. The structure defines a binding pocket formed by the four subdomains of the NACHT domain, and shows the inhibitor acts as an intramolecular glue, which locks the protein in an inactive conformation. It provides further molecular insight into our understanding of NLRP3 activation, helps to detail the residues involved in subdomain coordination within the NLRP3 NACHT domain, and gives molecular insights into how gain-of-function mutations de-stabilize the inactive conformation of NLRP3. Finally, it suggests stabilizing the auto-inhibited form of the NACHT domain is an effective way to inhibit NLRP3, and will aid the structure-based development of NLRP3 inhibitors for a range of inflammatory diseases.
- Published
- 2021
12. Degradation of recombinant proteins by Chinese hamster ovary host cell proteases is prevented by matriptase‐1 knockout
- Author
-
Benjamin Sommer, Christopher J. Farady, Joel Alois Rene Tapparel, Ursula Bodendorf, Edward J. Oakeley, Sandro Nuciforo, Sandrine Romand, Stine Buechmann-Moeller, and Holger Laux
- Subjects
0301 basic medicine ,Proteases ,medicine.medical_treatment ,Bioengineering ,CHO Cells ,Applied Microbiology and Biotechnology ,Chinese hamster ,03 medical and health sciences ,Cricetulus ,Cricetinae ,medicine ,Animals ,Humans ,Matriptase ,Cell Engineering ,chemistry.chemical_classification ,Transcription activator-like effector nuclease ,Protease ,biology ,Chemistry ,Chinese hamster ovary cell ,Serine Endopeptidases ,biology.organism_classification ,Recombinant Proteins ,Cell biology ,030104 developmental biology ,Cell culture ,Gene Knockdown Techniques ,Proteolysis ,biology.protein ,Glycoprotein ,Biotechnology - Abstract
An increasing number of nonantibody format proteins are entering clinical development. However, one of the major hurdles for the production of nonantibody glycoproteins is host cell-related proteolytic degradation, which can drastically impact developability and timelines of pipeline projects. Chinese hamster ovary (CHO) cells are the preferred production host for recombinant therapeutic proteins. Using protease inhibitors, transcriptomics, and genetic knockdowns, we have identified, out of the >700 known proteases in rodents, matriptase-1 as the major protease involved in the degradation of recombinant proteins expressed in CHO-K1 cells. Subsequently, matriptase-1 was deleted in CHO-K1 cells using "transcription activator-like effector nucleases" (TALENs) as well as zinc-finger nucleases (ZFNs). This resulted in a superior CHO-K1 matriptase (KO) cell line with strongly reduced or no proteolytic degradation activity toward a panel of recombinantly expressed proteins. The matriptase KO cell line was evaluated in spike-in experiments and showed little or no degradation of proteins incubated in culture supernatant derived from the KO cells. This effect was confirmed when the same proteins were recombinantly expressed in the KO cell line. In summary, the combination of novel cell line engineering tools, next-generation sequencing screening methods, and the recently published Chinese hamster genome has enabled the development of this novel matriptase KO CHO cell line capable of improving expression yields of intact therapeutic proteins.
- Published
- 2018
13. Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors
- Author
-
Simone Schleeger, Stephanie C. Paulding, Lori Andrews, Ryann E. Swale, Frederic Villard, Christopher J. Farady, Holger Sellner, Kenji Namoto, Robert J. Moreau, Michael Robinson, Finton Sirockin, Christian Wiesmann, Joachim Loup, Kathrin Schipp, and E. Valeur
- Subjects
Models, Molecular ,0301 basic medicine ,Macrocyclic Compounds ,Rhinovirus ,Stereochemistry ,030106 microbiology ,Clinical Biochemistry ,Molecular Conformation ,Pharmaceutical Science ,Microbial Sensitivity Tests ,Cysteine Proteinase Inhibitors ,Crystallography, X-Ray ,medicine.disease_cause ,Antiviral Agents ,Biochemistry ,Structure-Activity Relationship ,Viral Proteins ,03 medical and health sciences ,Solid-phase synthesis ,Drug Discovery ,Hydrolase ,medicine ,Humans ,3c protease ,Molecular Biology ,Dose-Response Relationship, Drug ,Chemistry ,Organic Chemistry ,3C Viral Proteases ,Cysteine Endopeptidases ,030104 developmental biology ,Drug Design ,Molecular Medicine ,Structure based - Abstract
The design and synthesis of macrocyclic inhibitors of human rhinovirus 3C protease is described. A macrocyclic linkage of the P1 and P3 residues, and the subsequent structure-based optimization of the macrocycle conformation and size led to the identification of a potent biochemical inhibitor 10 with sub-micromolar antiviral activity.
- Published
- 2018
14. Selective MALT1 paracaspase inhibition does not block TNF-α production downstream of TLR4 in myeloid cells
- Author
-
Frédéric Bornancin, Thomas Calzascia, Christopher J. Farady, Christine Huppertz, Natacha Stoehr, and Adeline Unterreiner
- Subjects
0301 basic medicine ,biology ,Chemistry ,Immunology ,Paracaspase ,NFKB1 ,Cell biology ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Downstream (manufacturing) ,030220 oncology & carcinogenesis ,Myeloid cells ,TLR4 ,biology.protein ,Immunology and Allergy ,Tumor necrosis factor alpha ,Signal transduction ,Caspase - Published
- 2017
15. Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD
- Author
-
Jonathan S. Serody, Jenny P.-Y. Ting, Christopher J. Farady, Vincenzo Bronte, Michael Loschi, Brent H. Koehn, Takao Iwawaki, Asim Saha, Govindarajan Thangavelu, Mark E. Cooper, Cameron McDonald-Hyman, Jamie Panthera, Lie Ma, Keli L. Hippen, Walker Krepps, Bruce R. Blazar, Josh Dysthe, Jeffrey S. Miller, Stephen C. Jameson, Robert Zeiser, Peter J. Murray, William J. Murphy, David H. Munn, Michael Zaiken, and Geoffrey R. Hill
- Subjects
Inflammasomes ,Receptor expression ,Immunology ,Graft vs Host Disease ,Inflammation ,Biochemistry ,Mice ,Adenosine Triphosphate ,In vivo ,medicine ,Extracellular ,Animals ,Receptor ,Mice, Knockout ,Apyrase ,Chemistry ,Myeloid-Derived Suppressor Cells ,Inflammasome ,Cell Biology ,Hematology ,medicine.disease ,Graft-versus-host disease ,Cancer research ,Female ,medicine.symptom ,medicine.drug - Abstract
Myeloid-derived suppressor cells (MDSCs) can subdue inflammation. In mice with acute graft-versus-host disease (GVHD), donor MDSC infusion enhances survival that is only partial and transient because of MDSC inflammasome activation early posttransfer, resulting in differentiation and loss of suppressor function. Here we demonstrate that conditioning regimen-induced adenosine triphosphate (ATP) release is a primary driver of MDSC dysfunction through ATP receptor (P2x7R) engagement and NLR pyrin family domain 3 (NLRP3) inflammasome activation. P2x7R or NLRP3 knockout (KO) donor MDSCs provided significantly higher survival than wild-type (WT) MDSCs. Although in vivo pharmacologic targeting of NLRP3 or P2x7R promoted recipient survival, indicating in vivo biologic effects, no synergistic survival advantage was seen when combined with MDSCs. Because activated inflammasomes release mature interleukin-1�� (IL-1��), we expected that IL-1�� KO donor MDSCs would be superior in subverting GVHD, but such MDSCs proved inferior relative to WT. IL-1�� release and IL-1 receptor expression was required for optimal MDSC function, and exogenous IL-1�� added to suppression assays that included MDSCs increased suppressor potency. These data indicate that prolonged systemic NLRP3 inflammasome inhibition and decreased IL-1�� could diminish survival in GVHD. However, loss of inflammasome activation and IL-1�� release restricted to MDSCs rather than systemic inhibition allowed non-MDSC IL-1�� signaling, improving survival. Extracellular ATP catalysis with peritransplant apyrase administered into the peritoneum, the ATP release site, synergized with WT MDSCs, as did regulatory T-cell infusion, which we showed reduced but did not eliminate MDSC inflammasome activation, as assessed with a novel inflammasome reporter strain. These findings will inform future clinical using MDSCs to decrease alloresponses in inflammatory environments.
- Published
- 2019
- Full Text
- View/download PDF
16. Extrinsic and intrinsic apoptosis activate pannexin‐1 to drive NLRP 3 inflammasome assembly
- Author
-
Christopher J. Farady, Benjamin Demarco, Kaiwen W. Chen, Andreas Boettcher, Petr Broz, Kateryna Shkarina, Rosalie Heilig, and Pawel Pelczar
- Subjects
Inflammasomes ,Apoptosis ,Connexins ,Mice ,0302 clinical medicine ,News & Views ,Cells, Cultured ,Caspase ,0303 health sciences ,Caspase 8 ,biology ,General Neuroscience ,Caspase 1 ,Intracellular Signaling Peptides and Proteins ,Pyroptosis ,Inflammasome ,3T3 Cells ,Articles ,3. Good health ,Cell biology ,Receptors, Estrogen ,Lytic cycle ,Caspases ,Protein Binding ,Signal Transduction ,medicine.drug ,Programmed cell death ,Mice, Transgenic ,Nerve Tissue Proteins ,General Biochemistry, Genetics and Molecular Biology ,Proinflammatory cytokine ,03 medical and health sciences ,NLR Family, Pyrin Domain-Containing 3 Protein ,medicine ,Animals ,Humans ,Molecular Biology ,Apoptosis/physiology ,Apoptosis Regulatory Proteins/metabolism ,Caspases/metabolism ,Connexins/physiology ,Embryo, Mammalian ,HEK293 Cells ,HeLa Cells ,Inflammasomes/metabolism ,Intracellular Signaling Peptides and Proteins/metabolism ,Mice, Inbred C57BL ,Multiprotein Complexes/metabolism ,NLR Family, Pyrin Domain-Containing 3 Protein/metabolism ,Nerve Tissue Proteins/physiology ,Phosphate-Binding Proteins/metabolism ,Protein Multimerization ,Receptors, Estrogen/metabolism ,Signal Transduction/physiology ,NLRP3 ,apoptosis ,gasdermin ,pannexin‐1 ,pyroptosis ,030304 developmental biology ,General Immunology and Microbiology ,Intrinsic apoptosis ,Phosphate-Binding Proteins ,Multiprotein Complexes ,biology.protein ,Apoptosis Regulatory Proteins ,030217 neurology & neurosurgery - Abstract
Pyroptosis is a form of lytic inflammatory cell death driven by inflammatory caspase-1, caspase-4, caspase-5 and caspase-11. These caspases cleave and activate the pore-forming protein gasdermin D (GSDMD) to induce membrane damage. By contrast, apoptosis is driven by apoptotic caspase-8 or caspase-9 and has traditionally been classified as an immunologically silent form of cell death. Emerging evidence suggests that therapeutics designed for cancer chemotherapy or inflammatory disorders such as SMAC mimetics, TAK1 inhibitors and BH3 mimetics promote caspase-8 or caspase-9-dependent inflammatory cell death and NLRP3 inflammasome activation. However, the mechanism by which caspase-8 or caspase-9 triggers cell lysis and NLRP3 activation is still undefined. Here, we demonstrate that during extrinsic apoptosis, caspase-1 and caspase-8 cleave GSDMD to promote lytic cell death. By engineering a novel Gsdmd D88A knock-in mouse, we further demonstrate that this proinflammatory function of caspase-8 is counteracted by caspase-3-dependent cleavage and inactivation of GSDMD at aspartate 88, and is essential to suppress GSDMD-dependent cell lysis during caspase-8-dependent apoptosis. Lastly, we provide evidence that channel-forming glycoprotein pannexin-1, but not GSDMD or GSDME promotes NLRP3 inflammasome activation during caspase-8 or caspase-9-dependent apoptosis.
- Published
- 2019
- Full Text
- View/download PDF
17. <scp>GSDMD</scp> membrane pore formation constitutes the mechanism of pyroptotic cell death
- Author
-
Lorenzo Sborgi, Sebastian Rühl, Sebastian Hiller, Daniel J. Müller, Henning Stahlberg, Christopher J. Farady, Petr Broz, Rosalie Heilig, Estefania Mulvihill, and Joka Pipercevic
- Subjects
Cell death ,0301 basic medicine ,Programmed cell death ,Inflammasomes ,Immunology ,Caspase 1 ,Atomic force microscopy ,Gasdermin ,Inflammation ,Pyroptosis ,Caspase-11 ,Article ,General Biochemistry, Genetics and Molecular Biology ,Cell membrane ,03 medical and health sciences ,medicine ,Molecular Biology ,Caspase ,General Immunology and Microbiology ,biology ,General Neuroscience ,Inflammasome ,Articles ,Cell biology ,030104 developmental biology ,Membrane ,medicine.anatomical_structure ,Caspases ,biology.protein ,Autophagy & Cell Death ,medicine.drug - Abstract
Pyroptosis is a lytic type of cell death that is initiated by inflammatory caspases. These caspases are activated within multi-protein inflammasome complexes that assemble in response to pathogens and endogenous danger signals. Pyroptotic cell death has been proposed to proceed via the formation of a plasma membrane pore, but the underlying molecular mechanism has remained unclear. Recently, gasdermin D (GSDMD), a member of the ill-characterized gasdermin protein family, was identified as a caspase substrate and an essential mediator of pyroptosis. GSDMD is thus a candidate for pyroptotic pore formation. Here, we characterize GSDMD function in live cells and in vitro. We show that the N-terminal fragment of caspase-1-cleaved GSDMD rapidly targets the membrane fraction of macrophages and that it induces the formation of a plasma membrane pore. In vitro, the N-terminal fragment of caspase-1-cleaved recombinant GSDMD tightly binds liposomes and forms large permeability pores. Visualization of liposome-inserted GSDMD at nanometer resolution by cryo-electron and atomic force microscopy shows circular pores with variable ring diameters around 20 nm. Overall, these data demonstrate that GSDMD is the direct and final executor of pyroptotic cell death., The EMBO Journal, 35 (16), ISSN:0261-4189, ISSN:1460-2075
- Published
- 2016
18. Fragment-Based Protein-Protein Interaction Antagonists of a Viral Dimeric Protease
- Author
-
Timothy M. Acker, Jonathan E. Gable, Charles S. Craik, Christopher J. Farady, Eric R. Gonzalez, Samu Melkko, Patrick Schweigler, Gregory M. Lee, and Kaitlin R. Hulce
- Subjects
Models, Molecular ,0301 basic medicine ,Magnetic Resonance Spectroscopy ,medicine.medical_treatment ,Druggability ,Plasma protein binding ,01 natural sciences ,Biochemistry ,chemistry.chemical_compound ,human herpesviruses ,Aminothiazole ,Models ,Drug Discovery ,General Pharmacology, Toxicology and Pharmaceutics ,biology ,Molecular Structure ,Chemistry ,Drug discovery ,Serine Endopeptidases ,Pharmacology and Pharmaceutical Sciences ,Infectious Diseases ,5.1 Pharmaceuticals ,Herpesvirus 8, Human ,Molecular Medicine ,Drug ,Development of treatments and therapeutic interventions ,Infection ,Human ,Protein Binding ,Proteases ,Stereochemistry ,Medicinal & Biomolecular Chemistry ,Article ,Protein–protein interaction ,Dose-Response Relationship ,03 medical and health sciences ,Structure-Activity Relationship ,Medicinal and Biomolecular Chemistry ,NMR spectroscopy ,medicine ,Humans ,Protease Inhibitors ,fragment-based screening ,Herpesvirus 8 ,Pharmacology ,Protease ,Dose-Response Relationship, Drug ,010405 organic chemistry ,Organic Chemistry ,Active site ,Molecular ,0104 chemical sciences ,High-Throughput Screening Assays ,030104 developmental biology ,Emerging Infectious Diseases ,biology.protein ,proteases ,Peptide Hydrolases ,dimer disruption - Abstract
Fragment-based drug discovery has shown promise as an approach for challenging targets such as protein-protein interfaces. We developed and applied an activity-based fragment screen against dimeric Kaposi's sarcoma-associated herpesvirus protease (KSHV Pr) using an optimized fluorogenic substrate. Dose-response determination was performed as a confirmation screen, and NMR spectroscopy was used to map fragment inhibitor binding to KSHV Pr. Kinetic assays demonstrated that several initial hits also inhibit human cytomegalovirus protease (HCMV Pr). Binding of these hits to HCMV Pr was also confirmed by NMR spectroscopy. Despite the use of a target-agnostic fragment library, more than 80 % of confirmed hits disrupted dimerization and bound to a previously reported pocket at the dimer interface of KSHV Pr, not to the active site. One class of fragments, an aminothiazole scaffold, was further explored using commercially available analogues. These compounds demonstrated greater than 100-fold improvement of inhibition. This study illustrates the power of fragment-based screening for these challenging enzymatic targets and provides an example of the potential druggability of pockets at protein-protein interfaces.
- Published
- 2016
19. Mechanisms of Macromolecular Protease Inhibitors
- Author
-
Charles S. Craik and Christopher J. Farady
- Subjects
Models, Molecular ,Proteases ,Serine Proteinase Inhibitors ,Macromolecular Substances ,medicine.medical_treatment ,Biochemistry ,Article ,alpha-2-Macroglobulin ,Scissile bond ,Catalytic Domain ,medicine ,Protease Inhibitors ,Molecular Biology ,Serpins ,Serine protease ,Protease ,biology ,Organic Chemistry ,Proteolytic enzymes ,Protein Structure, Tertiary ,Zymogen activation ,Biocatalysis ,biology.protein ,Molecular Medicine ,MASP1 ,Peptide Hydrolases ,Protein Binding - Abstract
Proteolytic enzymes are ubiquitous in all organisms and constitute 2–4% of the encoded gene products. They are critical for diverse biological processes such as digestion, blood clotting, host defense, pathogenic infection, viral replication, wound healing, and disease progression, to name a few. Because proteases trigger an irreversible event - the cleavage of a protein - their activity must be tightly controlled. Dysregulated proteolytic activity causes a disruption in the homeostatic balance of a biological system and can result in any number of poor biological outcomes. As a result, nature has developed a number of strategies to control proteolysis, including spatial and temporal regulation, zymogen activation and protease degradation, and through the inhibition of proteases by macromolecular inhibitors. Somewhat surprisingly, relatively few design principles underlie the mechanisms of inhibition of a myriad range of macromolecular protease inhibitors. Significant engineering efforts have gone into modifying and improving inhibitor potency and specificity, and to a large extent, the same design principles that work well for naturally occurring protease inhibitors have proved valuable for inhibitors developed in the laboratory. This review aims to survey the mechanisms by which macromolecular protease inhibitors function. To do this, inhibitors have been divided into categories based on their mechanism in order to illustrate that a relatively small number of design principles can be combined to develop new and effective protease inhibitors. These divisions are not strict, and many inhibitors could be grouped in a number of classes. The list of mechanisms presented here is not exhaustive in its treatment of all inhibitors, but aims to be illustrative of the many ways proteases can be inhibited. For more information on genome-wide protease mining,[1] protease mechanism,[2] pre-clinical inhibition,[3] and drug discovery efforts,[4] the reader is directed to excellent reviews that have been written in recent years. Figure 1 provides an overview of basic substrate and protease nomenclature that will be used in this review. Open in a separate window Figure 1 (A) Diagram of a protease active site. A protease cleaves a peptide at the scissile bond, and has a number of specificity subsites, which determine protease specificity. Substrates bind to a protease with their non-prime residues on the N-terminal side of the scissile bond and their prime-side residues C-terminal to the scissile bond. The catalytic residues determine the class of protease. Serine, cysteine, and threonine proteases hydrolyze a peptide bond via a covalent acyl-enzyme intermediate, and aspartic, glutamic and metalloproteases activate a water molecule to hydrolyze the peptide bond in a non-covalent manner. (B) A serine protease (matriptase/MT-SP1, 1EAX.pdb) with the catalytic triad in yellow and the surface loops that surround the active site colored in blue. While the catalytic architecture of proteases is remarkably conserved, the surface loops are areas of high sequential and structural diversity.
- Published
- 2010
20. Tumor Detection by Imaging Proteolytic Activity
- Author
-
Paul Phojanakong, Christopher J. Farady, Charles S. Craik, Byron Hann, Molly R. Darragh, James D. Marks, Jianlong Lou, and Eric L. Schneider
- Subjects
Diagnostic Imaging ,Cancer Research ,Transplantation, Heterologous ,Cell ,Fluorescent Antibody Technique ,Mice, Nude ,Biology ,Antibodies ,Article ,Mice ,Enzyme activator ,Antibody Specificity ,In vivo ,Neoplasms ,Biomarkers, Tumor ,Tumor Cells, Cultured ,medicine ,Animals ,Humans ,Matriptase ,Enzyme Inhibitors ,Serine Endopeptidases ,Cancer ,Biological activity ,medicine.disease ,Molecular biology ,Enzyme Activation ,medicine.anatomical_structure ,Oncology ,Cell culture ,Cancer cell ,biology.protein ,Female ,HT29 Cells ,Protein Processing, Post-Translational - Abstract
The cell surface protease membrane-type serine protease 1 [MT-SP1]/matriptase is often upregulated in epithelial cancers. A dysregulation in MT-SP1/matriptase levels with respect to its cognate inhibitor hepatocyte growth factor activator inhibitor-1 [HAI-1] suggests that it is an increase in proteolytic activity that significantly differentiates malignant from normal tissue. Here we use antibodies to demonstrate that MT-SP1 is active on cancer cells and that this activity may be targeted for tumor detection in vivo. A proteolytic activity assay with the MT-SP1-positive human cancer cell lines MCF-7, HT29, LNCaP, and MDA-MB-468 showed that the antibodies, which inhibit recombinant catalytic MT-SP1, are able to bind and inhibit the full-length enzyme. The same experiment with the MT-SP1-negative breast cancer cell lines MDA-MB-231, COLO 320DM and HT1080 showed no inhibition of proteolysis. Fluorescent microscopy then confirmed localization of labeled antibodies to the surface of MT-SP1-positive cells. To evaluate these antibodies as probes for targeting MT-SP1 activity in vivo, 0.7-2 nanomoles of fluorescently labeled antibodies were administered to xenograft mouse cancer models. The antibodies localized to the MT-SP1-positive MCF-7 and MCF-7/Luc+ tumors (n=3), permitting visualization of MT-SP1 activity. Fluorescence was not observed in MT-SP1-negative MDA-MD-231/Luc+ tumors (n=2), suggesting that MT-SP1 activity is a novel biomarker for epithelial cancer and these antibodies provide a non-invasive method for detecting this activity in vivo.
- Published
- 2010
21. Improving the species cross-reactivity of an antibody using computational design
- Author
-
Christopher J. Farady, Charles S. Craik, Benjamin D. Sellers, and Matthew P. Jacobson
- Subjects
Serine Proteinase Inhibitors ,medicine.drug_class ,In silico ,Clinical Biochemistry ,Pharmaceutical Science ,Cross Reactions ,Protein Engineering ,Monoclonal antibody ,medicine.disease_cause ,Biochemistry ,Cross-reactivity ,Antibodies ,Article ,Mice ,Species Specificity ,Antigen ,Drug Discovery ,medicine ,Animals ,Humans ,Molecular Biology ,Serine protease ,biology ,Chemistry ,Serine Endopeptidases ,Organic Chemistry ,Computational Biology ,Membrane Proteins ,Protein engineering ,In vitro ,Protein Structure, Tertiary ,Amino Acid Substitution ,Drug Design ,Mutation ,biology.protein ,Thermodynamics ,Molecular Medicine ,Antibody - Abstract
The high degree of specificity displayed by antibodies often results in varying potencies against antigen orthologs, which can affect the efficacy of these molecules in different animal models of disease. We have used a computational design strategy to improve the species cross-reactivity of an antibody-based inhibitor of the cancer-associated serine protease MT-SP1. In silico predictions were tested in vitro, and the most effective mutation, T98R, was shown to improve antibody affinity for the mouse ortholog of the enzyme 14-fold, resulting in an inhibitor with a K(I) of 340 pM. This improved affinity will be valuable when exploring the role of MT-SP1 in mouse models of cancer, and the strategy outlined here could be useful in fine-tuning antibody specificity.
- Published
- 2009
22. Structure of an Fab–Protease Complex Reveals a Highly Specific Non-canonical Mechanism of Inhibition
- Author
-
Pascal F. Egea, Christopher J. Farady, Molly R. Darragh, Charles S. Craik, and Eric L. Schneider
- Subjects
Models, Molecular ,Proteases ,Serine Proteinase Inhibitors ,Protein Conformation ,medicine.medical_treatment ,Molecular Sequence Data ,Crystallography, X-Ray ,Article ,Immunoglobulin Fab Fragments ,Structural Biology ,medicine ,Humans ,Binding site ,Molecular Biology ,chemistry.chemical_classification ,Serine protease ,Binding Sites ,Protease ,biology ,Serine Endopeptidases ,Protease inhibitor (biology) ,Enzyme ,chemistry ,Biochemistry ,biology.protein ,Antibody inhibitor ,medicine.drug - Abstract
The vast majority of protein protease inhibitors bind their targets in a substrate-like manner. This is a robust and efficient mechanism of inhibition, but due to the highly conserved architecture of protease active sites, these inhibitors often exhibit promiscuity. Inhibitors that show strict specificity for one protease usually achieve this selectivity by combining substrate-like binding in the active site with exosite binding on the protease surface. The development of new, specific inhibitors can be greatly aided by binding to non-conserved regions of proteases if potency can be maintained. Due to their ability to bind specifically to nearly any antigen, antibodies provide an excellent scaffold for creating inhibitors targeted to a single member of a family of highly homologous enzymes. The 2.2 Å resolution crystal structure of an Fab antibody inhibitor in complex with the serine protease membrane-type serine protease 1 (MT-SP1/matriptase) reveals the molecular basis of its picomolar potency and specificity. The inhibitor has a distinct mechanism of inhibition; it gains potency and specificity through interactions with the protease surface loops, and inhibits by binding in the active site in a catalytically non-competent manner. In contrast to most naturally occurring protease inhibitors, which have diverse structures but converge to a similar inhibitory archetype, antibody inhibitors provide an opportunity to develop divergent mechanisms of inhibition from a single scaffold.
- Published
- 2008
23. Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway
- Author
-
Maximiliano Vasquez, Christopher J. Farady, Keith T. Wilson, Alana L. Welm, Charles S. Craik, and Ami S. Bhatt
- Subjects
Male ,Transcription, Genetic ,medicine.medical_treatment ,Proteinase Inhibitory Proteins, Secretory ,Bone Marrow Cells ,Biology ,Nitric Oxide ,Receptor tyrosine kinase ,Substrate Specificity ,Mice ,Growth factor receptor ,Cell Line, Tumor ,parasitic diseases ,medicine ,Extracellular ,Animals ,Humans ,Cells, Cultured ,Oligonucleotide Array Sequence Analysis ,Multidisciplinary ,Activator (genetics) ,Gene Expression Profiling ,Growth factor ,Serine Endopeptidases ,Biological Sciences ,Macrophage Activation ,Recombinant Proteins ,Cell biology ,Gene expression profiling ,Macrophages, Peritoneal ,biology.protein ,Antibody inhibitor ,Female ,Signal transduction ,Signal Transduction - Abstract
A multidisciplinary method combining transcriptional data, specificity profiling, and biological characterization of an enzyme may be used to predict novel substrates. By integrating protease substrate profiling with microarray gene coexpression data from nearly 2,000 human normal and cancerous tissue samples, three fundamental components of a protease-activated signaling pathway were identified. We find that MT-SP1 mediates extracellular signaling by regulating the local activation of the prometastatic growth factor MSP-1. We demonstrate MT-SP1 expression in peritoneal macrophages, and biochemical methods confirm the ability of MT-SP1 to cleave and activate pro-MSP-1 in vitro and in a cellular context. MT-SP1 induced the ability of MSP-1 to inhibit nitric oxide production in bone marrow macrophages. Addition of HAI-1 or an MT-SP1-specific antibody inhibitor blocked the proteolytic activation of MSP-1 at the cell surface of peritoneal macrophages. Taken together, our work indicates that MT-SP1 is sufficient for MSP-1 activation and that MT-SP1, MSP-1, and the previously shown MSP-1 tyrosine kinase receptor RON are required for peritoneal macrophage activation. This work shows that this triad of growth factor, growth factor activator protease, and growth factor receptor is a protease-activated signaling pathway. Individually, MT-SP1 and RON overexpression have been implicated in cancer progression and metastasis. Transcriptional coexpression of these genes suggests that this signaling pathway may be involved in several human cancers.
- Published
- 2007
24. Kallikrein-related Peptidase 7
- Author
-
Christopher J. Farady, Lorenz M. Mayr, and Fabrice A. Kolb
- Subjects
Biochemistry ,Biophysics ,Kallikrein ,Peptidase 7 ,Biology - Published
- 2013
25. Contributors
- Author
-
Catherine Anne Abbott, Carmela R. Abraham, Hideki Adachi, Osao Adachi, Zach Adam, Michael W.W. Adams, Michael J. Adang, Ibrahim M. Adham, Patrizia Aducci, David A. Agard, Alexey A. Agranovsky, Tetsuya Akamatsu, Yoshinori Akiyama, Reidar Albrechtsen, Alí Alejo, Sean M. Amberg, Alexander Y. Amerik, Piti Amparyup, Felipe Andrade, Germán Andrés, Daniel M. Andrews, Robert K. Andrews, Toni M. Antalis, Colin S. Anthony, Naoya Aoki, Suneel S. Apte, Kazunari Arima, Gérard Arlaud, Raghuvir Krishnaswamy Arni, Pascal Arnoux, Nathan N. Aronson, Michel Arthur, Yasuhisa Asano, Paolo Ascenzi, Marina T. Assakura, David S. Auld, Veridiana de Melo Rodrigues Ávila, Francesc X. Avilés, William M. Awad, Anand K. Bachhawat, Shan Bai, Teaster T. Baird, S. Paul Bajaj, Susan C. Baker, Agnieszka Banbula, Alan J. Barrett, Jemima Barrowman, John D. Bartlett, Jörg W. Bartsch, Nikola Baschuk, Isolda P. Baskova, Jyotsna Batra, Karl Bauer, Ulrich Baumann, Wolfgang Baumeister, Cédric Bauvois, Alex Bayés, Anne Beauvais, Christoph Becker-Pauly, Tadhg P. Begley, Miklós Békés, Robert Belas, Daniah Beleford, Teruhiko Beppu, Ernst M. Bergmann, Bruno A. Bernard, Dominique Bernard, Michael C. Berndt, Giovanna Berruti, Colin Berry, Greg P. Bertenshaw, Christian Betzel, Chetana Bhaskarla, Manoj Bhosale, Gabriele Bierbaum, B. Bjarnason Jón, Michael Blaber, Michael J. Blackman, Alexander Blinkovsky, Jef D. Boeke, Matthew Bogyo, Stefan Bohn, Guy Boileau, Mike Boland, Tové C. Bolken, Judith S. Bond, Jan Bondeson, Javier Bordallo, Claudia Borelli, Tiago O. Botelho, Richard R. Bott, David G. Bourne, Niels Bovenschen, Ralph A. Bradshaw, Klaus Breddam, Keith Brew, Paul J. Brindley, Diane L. Brinkman, Collette Britton, Jeff R. Broadbent, Anne Broadhurst, Dieter Brómme, Murray Broom, Jeremy S. Brown, Mark A. Brown, Iris Bruchhaus, Barbara A. Burleigh, Kristin E. Burns, James F. Burrows, Michael J. Butler, David J. Buttle, Chelsea M. Byrd, Tony Byun, Sandrine Cadel, Conor R. Caffrey, Santiago Cal, Javier Caldentey, Thomas Candela, Clemente Capasso, Daniel R. Capriogilio, Vincenzo Carginale, Adriana Karaoglanovic Carmona, Vern B. Carruthers, Francis J. Castellino, Joseph J. Catanese, Bruce Caterson, George H. Caughey, Naimh X. Cawley, Tim E. Cawston, Juan José Cazzulo, Jijie Chai, Karl X. Chai, Olga Meiri Chaim, L.S. Chang, Julie Chao, Marie-Pierre Chapot-Chartier, Jean-Louis Charli, Paulette Charlier, Karen J. Chave, Jian-Min Chen, Jinq-May Chen, Li-Mei Chen, Ya-Wen Chen, Yu-Yen Chen, Bernard Chevrier, Jean-François Chich, Jeremy Chien, Suneeta Chimalapati, Ki Joon Cho, Kwan Yong Choi, Woei-Jer Chuang, Chin Ha Chung, Ivy Yeuk Wah Chung, Christine Clamagirand, Ian M. Clark, Adrian K. Clarke, Nicola E. Clarke, Steven Gerard Clarke, Philippe Clauziat, Judith A. Clements, Catherine Coffinier, Paul Cohen, Alain Colige, Anne Collignon, Sean D. Colloms, Andreas Conzelmann, Graham H. Coombs, Jakki C. Cooney, Jonathan B. Cooper, Max D. Cooper, Nikki A. Copeland, Graeme S. Cottrell, Joseph T. Coyle, Charles S. Craik, John W.M. Creemers, Daniela Cretu, Jenifer Croce, Keith J. Cross, Rosario Cueva, Sheng Cui, Luis Cunha, Simon Cutting, Christophe d’Enfert, Hugues D’Orchymont, Björn Dahlbäck, Shujia Dai, Ross E. Dalbey, John P. Dalton, Pam M. Dando, R.M. Daniel, Sergei M. Danilov, Donna E. Davies, Heloisa S. De Araujo, Teresa De los Santos, Viviana de Luca, Ingrid De Meester, Ana Karina de Oliveira, Eduardo Brandt de Oliveira, Pedro Lagerblad De Oliveira, Sarah de Vos, Jeroen Declercq, Wim Declercq, Ala-Eddine Deghmane, Niek Dekker, Sonia Del Prete, Marina Del Rosal, Bernard Delmas, Robert DeLotto, Ilya V. Demidyuk, Mark R. Denison, Jan M. Deussing, Lakshmi A. Devi, Eleftherios P. Diamandis, Isabel Diaz, Araceli Díaz-Perales, Bauke W. Dijkstra, Yan Ding, Jack E. Dixon, Johannes Dodt, Terje Dokland, Iztok Dolenc, Ningzheng Dong, Tran Cat Dong, Ying Dong, Mitesh Dongre, Mark Donovan, Timothy M. Dore, Loretta Dorstyn, Hong Dou, Zhicheng Dou, Annette M. Dougall, Marcin Drag, Edward G. Dudley, Ben M. Dunn, Bruno Dupuy, Maria Conceicāo Duque-Magalhāes, M. Asunción Durá, Yves Eeckhout, Vincent Eijsink, Arthur Z. Eisen, Azza Eissa, Sandra Eklund, Ziad M. Eletr, Vincent Ellis, Wolfgang Engel, Ervin G. Erdös, Teresa Escalante, David A. Estell, Michael Etscheid, Herbert J. Evans, Roger D. Everett, Alex C. Faesen, Falk Fahrenholz, Miriam Fanjul-Fernández, Christopher J. Farady, Georges Feller, Hong Feng, Kurt M. Fenster, Claude Férec, Silvia Ferrari, Barbara Fingleton, Jed F. Fisher, Paula M. Fives-Taylor, Loren G. Fong, F. Forneris, Brian M. Forster, Friedrich Forster, Simon J. Foster, Thierry Foulon, Stephen I. Foundling, Jay William Fox, Bruno Franzetti, Alejandra P. Frasch, Hudson H. Freeze, Jean-Marie Frère, Teryl K. Frey, Beate Fricke, Lloyd D. Fricker, Rafael Fridman, Christopher J. Froelich, Camilla Fröhlich, Hsueh-Liang Fu, Cynthia N. Fuhrmann, Satoshi Fujimura, Hiroshi Fujiwara, Jun Fukushima, Keiichi Fukuyama, Robert S. Fuller, Martin Fusek, Christine Gaboriaud, Christian Gache, Oleksandr Gakh, Peter Gal, Junjun Gao, Adolfo García-Sastre, Donald L. Gardiner, John A. Gatehouse, G.M. Gaucher, Francis Gauthier, Jean-Marie Ghuysen, Wade Gibson, Jennifer Gillies, Elzbieta Glaser, Fabian Glaser, Michael H. Glickman, Peter Goettig, Colette Goffin, Eiichi Gohda, Alfred L. Goldberg, Daniel E. Goldberg, Gregory I. Goldberg, Nathan E. Goldfarb, F. Xavier Gomis-Rüth, B. Gopal, Alexander E. Gorbalenya, Stuart G. Gordon, Mark D. Gorrell, Friedrich Götz, Theodoros Goulas, Cécile Gouzy-Darmon, K. Govind, Lászlo Gráf, Robert R. Granados, Melissa Ann Gräwert, Douglas A. Gray, Thomas P. Graycar, Jonathan A. Green, Luiza Helena Gremski, Michael Groll, Tania Yu Gromova, P. Gros, Marvin J. Grubman, Amy M. Grunden, Ágústa Gudmundsdóttir, Micheline Guinand, Djamel Gully, Alla Gustchina, José María Gutiérrez, Byung Hak Ha, Jesper Z. Haeggström, James H. Hageman, Johanna Haiko, Stephan Hailfinger, Hans Michael Haitchi, Ji Seon Han, Chantal Hanquez, Minoru Harada, Ikuko Hara-Nishimura, Marianne Harboe, Torleif Härd, David A. Harris, Ulrich Hassiepen, Shoji Hata, Akira Hattori, Rong-Qiao He, Albert J.R. Heck, Dirk F. Hendricks, Bernhard Henrich, Patrick Henriet, Andrés Hernández-Arana, Irma Herrera-Camacho, Gerhard Heussipp, Toshihiko Hibino, P.M. Hicks, Bradley I. Hillman, B. Yukihiro Hiraoka, Jun Hiratake, Yohei Hizukuri, Heng-Chien Ho, Ngo Thi Hoa, Mark Hochstrasser, Kathryn M. Hodge, Theo Hofmann, Thomas Hohn, John R. Hoidal, Joachim-Volker Höltje, Koichi J. Homma, John F. Honek, Vivian Y.H. Hook, John D. Hooper, Nigel M. Hooper, Kazuo Hosoi, Christopher J. Howe, Dennis E. Hruby, James J.-D. Hseih, Chun-Chieh Hsu, Tony T. Huang, Tur-Fu Huang, Yoann Huet, Clare Hughes, Jean-Emmanuel Hugonnet, Adrienne L. Huston, Oumaïma Ibrahim-Granet, Eiji Ichishima, Yukio Ikehara, Tadashi Inagami, Jessica Ingram, R.E. Isaac, Grazia Isaya, Clara E. Isaza, Shin-ichi Ishii, Amandine Isnard, Kiyoshi Ito, Koreaki Ito, Yoshifumi Itoh, Xavier Iturrioz, Sadaaki Iwanaga, Ralph W. Jack, Mel C. Jackson, Michael N.G. James, Jiří Janata, Claire Janoir, Hanna Janska, Ken F. Jarrell, Mariusz Jaskolski, Sheila S. Jaswal, Ying Y. Jean, Dieter E. Jenne, Young Joo Jeon, Ping Jiang, John E. Johnson, Michael D. Johnson, James A. Johnston, Amanda Jones, Elizabeth W. Jones, Carine Joudiou, Luiz Juliano, Hea-Jin Jung, Ray Jupp, Todd F. Kagawa, Hubert Kalbacher, Yayoi Kamata, Shuichi Kaminogawa, Yoshiyuki Kamio, Makoto Kaneda, Sung Gyun Kang, Sung Hwan Kang, Mary Kania, Tomasz Kantyka, Nobuyuki Kanzawa, Abdulkarim Y. Karim, Takafumi Kasumi, Hiroaki Kataoka, Hardeep Kaur, Shun-Ichiro Kawabata, Mari Kawaguchi, John Kay, Murat Kaynar, Kenneth C. Keiler, R.M. Kelly, Nathaniel T. Kenton, Michael A. Kerr, Kristof Kersse, Jukka Kervinen, Benedikt M. Kessler, Efrat Kessler, Timo K. Khoronen, Simon Kidd, Marjolein Kikkert, Mogens Kilian, Do-Hyung Kim, Doyoun Kim, Eunice EunKyeong Kim, In Seop Kim, Jung-Gun Kim, Kyeong Kyu Kim, Kyung Hyun Kim, Matthew S. Kimber, Yukio Kimura, Heidrun Kirschke, Yoshiaki Kiso, Colin Kleanthous, Jürgen R. Klein, Michael Klemba, Beata Kmiec, Hideyuki Kobayashi, Hiroyuki Kodama, Gerald Koelsch, Jan Kok, P.E. Kolattukody, Fabrice A. Kolb, Harald Kolmar, Yumiko Komori, Jan Konvalinka, Brice Korkmaz, Sergey V. Kostrov, Hans-Georg Kräusslich, Gabi Krczal, Lawrence F. Kress, Magnüs Már Kristjánsson, Tomáš Kučera, Sayali S. Kukday, Hidehiko Kumagai, Sharad Kumar, Malika Kumarasiri, Takashi Kumazaki, Beate M. Kümmerer, Kouji Kuno, Markku Kurkinen, Eva Kutejová, Marie Kveiborg, Agnieszka Kwarciak, Liisa Laakkonen, Nikolaos E. Labrou, Gavin D. Laing, Gayle Lamppa, Thomas Langer, Richard A. Laursen, Richard A. Lawrenson, Matthew D. Layne, Bernard F. Le Bonniec, María C. Leal, Ronald M. Lechan, David H. Lee, Irene Lee, Jae Lee, Kye Joon Lee, Soohee Lee, Xiaobo Lei, Jonathan Leis, Ellen K. LeMosy, Thierry Lepage, Stephen H. Leppla, Adam Lesner, Ivan A.D. Lessard, Guy Lhomond, Huilin Li, Shu-Ming Li, Weiguo Li, Ta-Hsiu Liao, Robert C. Liddington, Toby Lieber, H.R. Lijnen, Christopher D. Lima, Chen-Yong Lin, Gang Lin, Ming T. Lin, Xinli Lin, Yee-Shin Lin, L.L. Lindsay, William N. Lipscomb, John W. Little, Ching-Chuan Liu, Chuan-ju Liu, Mark O. Lively, Nurit Livnat-Levanon, Per O. Ljungdahl, Catherine Llorens-Cortes, Peter Lobel, Y. Peng Loh, Jouko Lohi, G.P. Lomonossoff, Yvan Looze, Carlos López-Otin, Landys Lopez-Quezada, Alex Loukas, Long-Sheng Lu, Áke Lundwall, Liu-Ying Luo, Andrei Lupas, Dawn S. Luthe, Nicholas J. Lynch, Peter J. Lyons, Vivian L. MacKay, Jesica M. Levingston Macleod, Viktor Magdolen, Jean-Luc Mainardi, Kauko K. Mäkinen, Jeremy P. Mallari, Surya P. Manandhar, Fajga R. Mandelbaum, Anne M. Manicone, Johanna Mansfeld, Joseph Marcotrigiano, Michael Mares, Gemma Marfany, Francis S. Markland, Judith Marokházi, Hélène Marquis, Robert A. Marr, Enzo Martegani, Erik W. Martin, Manuel Martinez, L. Miguel Martins, Masato Maruyama, Masugi Maruyama, Sususmu Maruyama, Takeharu Masaki, Ramin Massoumi, Rency T. Mathew, Lynn M. Matrisian, Yoshihiro Matsuda, Osamu Matsushita, Marco Matuschek, Anna Matušková, Krisztina Matúz, Cornelia Mauch, Michael R. Maurizi, Lorenz M. Mayr, Dewey G. McCafferty, J. Ken McDonald, James H. McKerrow, David McMillan, Robert P. Mecham, Darshini P. Mehta, Chris Meisinger, Alan Mellors, Roger G. Melton, Jeffrey A. Melvin, Robert Ménard, Luis Menéndez-Arias, Milene C. Menezes, Andrew Mesecar, Stéphane Mesnage, Diane H. Meyer, Gregor Meyers, Susan Michaelis, Karolina Michalska, Wojciech P. Mielicki, Igor Mierau, Galina V. Mikoulinskaia, Charles G. Miller, Lydia K. Miller, John Mills, Kenneth V. Mills, Jinrong Min, Michel-Yves Mistou, Yoshio Misumi, Shin-ichi Miyoshi, Shigehiko Mizutani, Shahriar Mobashery, Satsuki Mochizuki, William L. Mock, Frank Möhrlen, Nathalie Moiré, Paul E. Monahan, Angela Moncada-Pazos, Véronique Monnet, Michel Monod, Cesare Montecucco, Laura Morelli, Sumiko Mori, Takashi Morita, James H. Morrissey, Richard J. Morse, John S. Mort, Uffe H. Mortensen, Rory E. Morty, Joel Moss, Hidemasa Motoshima, Jeremy C. Mottram, Ana M. Moura-da-Silva, Mary Beth Mudgett, Egbert Mundt, Kazuo Murakami, Mario Tyago Murakami, Kimiko MurakamiMurofoshi, Sawao Murao, Gillian Murphy, M.R.N. Murthy, Tatsushi Muta, Elmarie Myburgh, Nino Mzhavia, A.H.M. Nurun Nabi, Hideaki Nagase, Michael W. Nagle, Dorit K. Nägler, Rajesh R. Naik, Divya B. Nair, Toshiki Nakai, Yoshitaka Nakajima, Yukio Nakamura, Hitoshi Nakatogawa, Toru Nakayama, Natalia N. Nalivaeva, Dipankar Nandi, Maria Clara Leal Nascimento-Silva, Kim Nasmyth, Carl F. Nathan, Fernando Navarro-García, Dayane Lorena Naves, Danny D. Nedialkova, Keir C. Neuman, Jeffrey-Tri Nguyen, Ky-Anh Nguyen, Gabriela T. Niemirowicz, Toshiaki Nikai, Eiichiro Nishi, Wataru Nishii, Makoto Nishiyama, Yasuhiro Nishiyama, Masatoshi Noda, Seiji Nomura, Shigemi Norioka, Desire M.M. Nsangou, Amornrat O’Brien, Michael B. O’Connor, Kohei Oda, Irina V. Odinokova, Joyce Oetjen, Teru Ogura, Dennis E Ohman, Yoshinori Ohsumi, Mukti Ojha, Akinobu Okabe, Yasunori Okada, Keinosuke Okamoto, Kenji Okuda, Nobuaki Okumura, Takashi Okuno, Kjeld Oleson, Priscila Oliveira de Giuseppe, Martin Olivier, Yasuko Ono, Stephen Oroszlan, Nobuyuki Ota, Michael Ovadia, Jiyang O-Wang, Claus Oxvig, Jeremy C.L. Packer, Sergio Padilla-López, Mark Paetzel, Michael J. Page, Andrea Page-McCaw, Mark J.I. Paine, Byoung Chul Park, Eunyong Park, John E. Park, Pyong Woo Park, Sung Goo Park, Kirk L. Parkin, William C Parks, Thaysa Paschoalin, Annalisa Pastore, Alexander Nikolich Patananan, Sudhir Paul, Henry L. Paulson, Ulrich von Pawel-Rammingen, David A. Pearce, Mark S. Pearson, Duanqing Pei, Gunnar Pejler, Alan D. Pemberton, Jianhao Peng, Julien Pernier, Jan-Michael Peters, Thorsten Pfirrmann, Viet-Laï Pham, Iva Pichová, Darren Pickering, Christophe Piesse, David Pignol, Robert N. Pike, Lothaire Pinck, Hubert Pirkle, Henry C. Pitot, Andrew G. Plaut, Hidde Ploegh, László Polgár, Corrine Porter, Rolf Postina, Jan Potempa, Knud Poulsen, Scott D. Power, Rex. F. Pratt, Gerd Prehna, Gilles Prévost, Alexey V. Pshezhetsky, Mohammad A. Qasim, Feng Qian, Jiazhou Qiu, Víctor Quesada, Evette S. Radisky, Stephen D. Rader, Kavita Raman, Andrew J. Ramsay, Derrick E. Rancourt, Najju Ranjit, Narayanam V. Rao, Kiira Ratia, Neil D. Rawlings, Robert B. Rawson, Vijay Reddy, Colvin M. Redman, Maria Elena Regonesi, Andreas S. Reichert, Antonia P. Reichl, Han Remaut, S. James Remington, Martin Renatus, David Reverter, Eric C. Reynolds, Mohamed Rholam, Charles M. Rice, Todd W. Ridky, Howard Riezman, D.C. Rijken, Marie-Christine Rio, Alison Ritchie, Janine Robert-Baudouy, Mark W. Robinson, Michael Robinson, Adela Rodriguez-Romero, Renata Santos Rodriques, John C. Rogers, Camilo Rojas, Floyd E. Romesberg, David J. Roper, Nora Rosas-Murrieta, A.M. Rose, Philip J. Rosenthal, J. Rosing, Ornella Rossetto, Véronique Rossi, Richard A. Roth, Hanspeter Rottensteiner, Andrew D. Rowan, Mikhail Rozanov, Alexandra Rucavado, Andrea Ruecker, Françoise Rul, Till Rümenapf, Ilaria Russo, Martin D. Ryan, Elena Sacco, J. Evan Sadler, W. Saenger, Hans-Georg Sahl, Mohammed Sajid, Masayoshi Sakaguchi, Fumio Sakiyama, Maria L. Salas, Maria Cristina O. Salgado, Guy S. Salvesen, Edith Sánchez, Eladio F. Sanchez, Qing-Xiang Amy Sang, Krishnan Sankaran, Susanta K. Sarkar, Michael P. Sarras, Yoshikiyo Sasagawa, Araki Satohiko, Eric Sauvage, Loredana Saveanu, H.S. Savithri, Hitoshi Sawada, R. Gary Sawers, Isobel A. Scarisbrick, Andreas Schaller, Justin M. Scheer, Friedrich Scheiflinger, Cordelia Schiene-Fischer, Uwe Schlomann, Manfred Schlösser, Alvin H. Schmaier, Walter K. Schmidt, Anette Schneemann, Rick G. Schnellmann, Henning Scholze, Lutz Schomburg, Wilhelm J. Schwaeble, Christopher J. Scott, Rosaria Scudiero, Atsuko Sehara-Fujisawa, Nabil G. Seidah, Motoharu Seiki, Junichi Sekiguchi, Andrea Senff-Ribeiro, Ihn Sik Seong, Mihaela Serpe, Solange M.T. Serrano, Peter Setlow, Tina Shahian, M. Shanks, Feng Shao, Steven D. Shapiro, Navneet Sharma, Lindsey N. Shaw, Aimee Shen, Lei Shen, Roger F. Sherwood, Yun-Bo Shi, Hitoshi Shimoi, Yoichiro Shimura, A.D. Shirras, Viji Shridhar, Jinal K. Shukla, Ene Siigur, Jüri Siigur, Natalie C. Silmon de Monerri, Robert B. Sim, James P. Simmer, William H. Simmons, Jaspreet Singh, Alison Singleton, Tatiana D. Sirakova, Titia K. Sixma, Tim Skern, Randal A. Skidgel, Jeffrey Slack, David E. Sleat, Barbara S. Slusher, Janet L. Smith, Matthew A. Smith, Mark J. Smyth, Erik J. Snijder, Solmaz Sobhanifar, Kenneth Söderhaäll, Istvan Sohar, Peter Sonderegger, Marcos Henrique Ferreira Sorgine, Hiroyuki Sorimachi, Karen E. Soukhodolets, Tatiana de Arruda Campos Brasil de Souza, Tamás Sperka, Shiranee Sriskandan, Joseph W. St. Geme, Raymond J. St. Leger, Peter Staib, James L. Steele, Bjarki Stefansson, Christian Steinkühler, Leisa M. Stenberg, Johan Stenflo, Henning R. Stennicke, Valentin M. Stepanov, Olga A. Stepnaya, Frank Steven, Richard L. Stevens, Kenneth J. Stevenson, Mathieu St-Louis, Christopher C. Stobart, Walter Stöcker, Andrew C. Storer, Norbert Sträter, Ellen G. Strauss, James H. Strauss, Kvido Stříšovský, Natalie C.J. Strynadka, Edward D. Sturrock, Dan Su, Xiao-Dong Su, Paz Suárez-Rendueles, Traian Sulea, Venkatesh Sundararajan, Ryoji Suno, Carolyn K. Suzuki, Fumiaki Suzuki, Hideyuki Suzuki, Nobuhiro Suzuki, Stephen Swenson, Rose L. Szabady, Pal Bela Szecsi, Lászlo Szilágyi, Muhamed-Kheir Taha, Eizo Takahashi, Kenji Takahashi, Toshiro Takai, Atsushi Takeda, Soichi Takeda, Jeremy J.R.H. Tame, Tomohiro Tamura, Fulong Tan, Keiji Tanaka, Carmen Tanase, Jordan Tang, Martha M. Tanizaki, Egbert Tannich, Guido Tans, Anthony L. Tarentino, Anchalee Tassanakajon, Hiroki Tatsumi, Norbert Tautz, Erin Bassford Taylor, Pedro Filipe Teixeira, Bhanu Prakash V.L. Telugu, Markus F. Templin, Shigeyuki Terada, Uchikoba Tetsuya, C. Thacker, Maulik Thaker, Heinz-Jürgen Thiel, Nicole Thielens, Gonzales Thierry, Karine Thivierge, Mark D. Thomas, Margot Thome, Mary K. Thorsness, Peter E. Thorsness, Natalie J. Tigue, Sokol V. Todi, Birgitta Tomkinson, Fiorella Tonello, Liang Tong, H.S. Toogood, Paolo Tortora, József Tözsèr, Luiz Rodolpho Travassos, James Travis, Dilza Trevisan-Silva, Francesca Trinchella, Neil N. Trivedi, Carol M. Troy, Harald Tschesche, Yu-Lun Tseng, Masafumi Tsujimoto, Anthony T. Tu, Kathleen E. Tumelty, Boris Turk, Dusan Turk, Vito Turk, Anthony J. Turner, Tetsuya Uchikoba, Takayuki Ueno, Alejandro P. Ugalde, Veli-Jukka Uitto, Sinisa Urban, Olivier Valdenaire, Adrian Valli, Jozef Van Beeumen, Bertus Van den Burg, Renier A.L. Van der Hoorn, Jan Maarten van Dijl, Peter Van Endert, Bram J. Van Raam, Harold E. Van Wart, Tom Vanden Berghe, Peter Vandenabeele, Margo Vanoni, Silvio Sanches Veiga, William H. Velander, Gloria Velasco, Josep Vendrell, I. István Venekei, Vaclav Vetvicka, F.-Nora Vögtle, Waldemar Vollmer, Kei Wada, Fred W. Wagner, Sun Nyunt Wai, Timothy Wai, Shane Wainwright, Kenneth W. Walker, Stephen J. Walker, Jean Wallach, Linda L. Walling, Peter N. Walsh, Hai-Yan Wang, Hengbin Wang, Jianwei Wang, Peng Wang, Ping Wang, Michael Wassenegger, Kunihiko Watanabe, Helen Webb, Joseph M. Weber, Niklas Weber, Daniel R. Webster, Shuo Wei, Rodney A. Welch, James A. Wells, Herbert Wenzel, Ingrid E. Wertz, Ulla W. Wewer, Alison R. Whyteside, Sherwin Wilk, Jean-Marc Wilkin, Claudia Wilmes, Jakob R. Winther, David S. Wishart, Alexander Wlodawer, J. Fred Woessner, Michael S. Wolfe, Wilson Wong, Roger Woodgate, Gerry Wright, Jiunn-Jong Wu, Qingyu Wu, Magdalena Wysocka, Chao Xu, Zhenghong Xu, Kinnosuke Yahori, Shoji Yamada, Nozomi Yamaguchi, Shinji Yamaguchi, Yoshio Yamakawa, Hiroki Yamamoto, Ikao Yana, Maozhou Yang, Na Yang, Chenjuan Yao, Tingting Yao, Noriko Yasuda, Toshimasa Yasuhara, Shigeki Yasumasu, Edward T.H. Yeh, Irene Yiallouros, Jiang Yin, Hiroo Yonezawa, Soon Ji Yoo, Tadashi Yoshimoto, Michael W. Young, Stephen G. Young, Nousheen Zaidi, Ludmila L. Zavalova, Peter Zavodszky, Aidong Zhang, Xianming Zhang, Yi-Zheng Zhang, Dominick Zheng, Guangming Zhong, Rong Zhong, Yuan Zhou, Zhaohui Sunny Zhou, Michael Zick, Paola Zigrino, and Andrei A. Zimin
- Published
- 2013
26. A reverse binding motif that contributes to specific protease inhibition by antibodies
- Author
-
Mick Ward, Eric L. Schneider, Christopher J. Farady, Charles S. Craik, Aida Baharuddin, David H. Goetz, Cheng-I Wang, and Melody Lee
- Subjects
Models, Molecular ,Proteases ,Phage display ,medicine.medical_treatment ,Molecular Sequence Data ,Antibodies ,Catalysis ,Article ,Serine ,Immunoglobulin Fab Fragments ,Structural Biology ,Peptide Library ,Catalytic Domain ,medicine ,Humans ,Matriptase ,Protease Inhibitors ,Protein Interaction Domains and Motifs ,Amino Acid Sequence ,Molecular Biology ,Serine protease ,Protease ,biology ,Sequence Homology, Amino Acid ,Serine Endopeptidases ,Transmembrane protein ,Biochemistry ,biology.protein ,Mutagenesis, Site-Directed ,Antibody inhibitor ,Peptide Hydrolases - Abstract
The type II transmembrane serine protease family consists of 18 closely related serine proteases that are implicated in multiple functions. To identify selective, inhibitory antibodies against one particular type II transmembrane serine protease, matriptase [MT-SP1 (membrane-type serine protease 1)], a phage display library was created with a natural repertoire of Fabs [fragment antigen binding (Fab)] from human naive B cells. Fab A11 was identified with a 720 pM inhibition constant and high specificity for matriptase over other trypsin-fold serine proteases. A Trichoderma reesei system expressed A11 with a yield of ∼ 200 mg/L. The crystal structure of A11 in complex with matriptase has been determined and compared to the crystal structure of another antibody inhibitor (S4) in complex with matriptase. Previously discovered from a synthetic single-chain variable fragment library, S4 is also a highly selective and potent matriptase inhibitor. The crystal structures of the A11/matriptase and S4/matriptase complexes were solved to 2.1 A and 1.5 A, respectively. Although these antibodies, discovered from separate libraries, interact differently with the protease surface loops for their specificity, the structures reveal a similar novel mechanism of protease inhibition. Through the insertion of the H3 variable loop in a reverse orientation at the substrate-binding pocket, these antibodies bury a large surface area for potent inhibition and avoid proteolytic inactivation. This discovery highlights the critical role that the antibody scaffold plays in positioning loops to bind and inhibit protease function in a highly selective manner. Additionally, Fab A11 is a fully human antibody that specifically inhibits matriptase over other closely related proteases, suggesting that this approach could be useful for clinical applications.
- Published
- 2011
27. ChemInform Abstract: Mechanisms of Macromolecular Protease Inhibitors
- Author
-
Christopher J. Farady and Charles S. Craik
- Subjects
Serine protease ,Proteases ,Protease ,biology ,medicine.diagnostic_test ,Chemistry ,medicine.medical_treatment ,Proteolysis ,Proteolytic enzymes ,General Medicine ,Scissile bond ,Biochemistry ,Zymogen activation ,Catalytic triad ,biology.protein ,medicine - Abstract
Proteolytic enzymes are ubiquitous in all organisms and constitute 2–4% of the encoded gene products. They are critical for diverse biological processes such as digestion, blood clotting, host defense, pathogenic infection, viral replication, wound healing, and disease progression, to name a few. Because proteases trigger an irreversible event - the cleavage of a protein - their activity must be tightly controlled. Dysregulated proteolytic activity causes a disruption in the homeostatic balance of a biological system and can result in any number of poor biological outcomes. As a result, nature has developed a number of strategies to control proteolysis, including spatial and temporal regulation, zymogen activation and protease degradation, and through the inhibition of proteases by macromolecular inhibitors. Somewhat surprisingly, relatively few design principles underlie the mechanisms of inhibition of a myriad range of macromolecular protease inhibitors. Significant engineering efforts have gone into modifying and improving inhibitor potency and specificity, and to a large extent, the same design principles that work well for naturally occurring protease inhibitors have proved valuable for inhibitors developed in the laboratory. This review aims to survey the mechanisms by which macromolecular protease inhibitors function. To do this, inhibitors have been divided into categories based on their mechanism in order to illustrate that a relatively small number of design principles can be combined to develop new and effective protease inhibitors. These divisions are not strict, and many inhibitors could be grouped in a number of classes. The list of mechanisms presented here is not exhaustive in its treatment of all inhibitors, but aims to be illustrative of the many ways proteases can be inhibited. For more information on genome-wide protease mining,[1] protease mechanism,[2] pre-clinical inhibition,[3] and drug discovery efforts,[4] the reader is directed to excellent reviews that have been written in recent years. Figure 1 provides an overview of basic substrate and protease nomenclature that will be used in this review. Open in a separate window Figure 1 (A) Diagram of a protease active site. A protease cleaves a peptide at the scissile bond, and has a number of specificity subsites, which determine protease specificity. Substrates bind to a protease with their non-prime residues on the N-terminal side of the scissile bond and their prime-side residues C-terminal to the scissile bond. The catalytic residues determine the class of protease. Serine, cysteine, and threonine proteases hydrolyze a peptide bond via a covalent acyl-enzyme intermediate, and aspartic, glutamic and metalloproteases activate a water molecule to hydrolyze the peptide bond in a non-covalent manner. (B) A serine protease (matriptase/MT-SP1, 1EAX.pdb) with the catalytic triad in yellow and the surface loops that surround the active site colored in blue. While the catalytic architecture of proteases is remarkably conserved, the surface loops are areas of high sequential and structural diversity.
- Published
- 2011
28. Vinyl sulfones as antiparasitic agents and a structural basis for drug design
- Author
-
Iain D. Kerr, Jennifer Legac, Mohammed Sajid, Conor R. Caffrey, Linda S. Brinen, Christopher J. Farady, Elizabeth Hansell, Kailash C. Pandey, Charles S. Craik, Ji Hyun Lee, Rachael Marion, Mathias Rickert, James H. McKerrow, and Philip J. Rosenthal
- Subjects
Proteases ,Trypanosoma cruzi ,Plasmodium falciparum ,Trypanosoma brucei brucei ,Protozoan Proteins ,Biology ,Crystallography, X-Ray ,Biochemistry ,chemistry.chemical_compound ,Animals ,Chagas Disease ,Protease Inhibitors ,Sulfones ,Malaria, Falciparum ,Molecular Biology ,Binding selectivity ,chemistry.chemical_classification ,Antiparasitic Agents ,Cell Biology ,Cysteine protease ,Antiparasitic agent ,Small molecule ,Protein Structure, Tertiary ,Papain ,Cysteine Endopeptidases ,Kinetics ,Enzyme ,Trypanosomiasis, African ,chemistry ,Drug Design ,Protein Structure and Folding ,Cysteine ,Protein Binding - Abstract
Cysteine proteases of the papain superfamily are implicated in a number of cellular processes and are important virulence factors in the pathogenesis of parasitic disease. These enzymes have therefore emerged as promising targets for antiparasitic drugs. We report the crystal structures of three major parasite cysteine proteases, cruzain, falcipain-3, and the first reported structure of rhodesain, in complex with a class of potent, small molecule, cysteine protease inhibitors, the vinyl sulfones. These data, in conjunction with comparative inhibition kinetics, provide insight into the molecular mechanisms that drive cysteine protease inhibition by vinyl sulfones, the binding specificity of these important proteases and the potential of vinyl sulfones as antiparasitic drugs.
- Published
- 2009
29. Protease Inhibitors: Mechanisms
- Author
-
Christopher J. Farady and Charles S. Craik
- Subjects
chemistry.chemical_classification ,Protease ,Enzyme ,biology ,Biochemistry ,chemistry ,medicine.medical_treatment ,biology.protein ,medicine ,Active site ,Design elements and principles ,Substrate (chemistry) ,Binding site - Abstract
Relatively few design principles underlie the mechanisms of inhibition of a myriad range of protease inhibitors. Protease inhibitors tend to be competitive and to compete with substrate binding, either through direct competition or deformation of the protease active site. Although protein inhibitors can gain potency through the burial of a large surface area and specificity through contacts with specific exosites, small-molecule inhibitors primarily gain potency through interactions with the catalytic machinery of the enzyme and specificity through interactions with the substrate binding sites. Incorporation of these design principles into chemical probes and drugs have improved greatly our ability to create potent and specific protease inhibitors.
- Published
- 2008
30. Structural Characterization and Determinants of Specificity of Single-Chain Antibody Inhibitors of Membrane-Type Serine Protease 1
- Author
-
Christopher J Farady
- Subjects
Serine protease ,Protease ,biology ,medicine.medical_treatment ,Mutagenesis ,medicine.disease ,Molecular biology ,Epithelium ,Metastasis ,Serine ,medicine.anatomical_structure ,Biochemistry ,In vivo ,medicine ,biology.protein ,Antibody - Abstract
Membrane-type serine protease 1 (MT-SP1) is a cancer-associated serine protease implicated in the tumorogenesis and metastasis of breast cancer. Inhibition of MT-SP1 activity has been shown to decrease metastatic potential. We have developed a number of potent and specific single-chain (scFv) antibody inhibitors to MT-SP1, and have begun to characterize their mechanism of inhibition. Through kinetic characterization and site-directed mutagenesis experiments, it has been determined that three potent inhibitors have separate and novel mechanisms of inhibition which do not mimic either biologically or pharmaceutically relevant protease inhibitors. These novel modes of binding and inhibition are the basis for their specificity, and suggest these inhibitors will have less cross-reactivity and toxicity problems when used in vivo to further dissect the role of MT-SP1 in breast cancer.
- Published
- 2008
31. The Mechanism of Inhibition of Antibody-Based Inhibitors of Membrane-Type Serine Protease 1 (MT-SP1)
- Author
-
Christopher J. Farady, Susan M. Miller, Molly R. Darragh, Jeonghoon Sun, and Charles S. Craik
- Subjects
Models, Molecular ,Serine Proteinase Inhibitors ,medicine.medical_treatment ,Immunoglobulin Variable Region ,Epitope ,Article ,Epitopes ,Structural Biology ,medicine ,Animals ,Humans ,Point Mutation ,Matriptase ,Molecular Biology ,chemistry.chemical_classification ,Serine protease ,Protease ,biology ,Serine Endopeptidases ,Active site ,Alanine scanning ,Protein Structure, Tertiary ,Enzyme ,chemistry ,Biochemistry ,biology.protein - Abstract
The mechanisms of inhibition of two novel scFv antibody inhibitors of the serine protease MT-SP1/matriptase reveal the basis of their potency and specificity. Kinetic experiments characterize the inhibitors as extremely potent inhibitors with K(I) values in the low picomolar range that compete with substrate binding in the S1 site. Alanine scanning of the loops surrounding the protease active site provides a rationale for inhibitor specificity. Each antibody binds to a number of residues flanking the active site, forming a unique three-dimensional binding epitope. Interestingly, one inhibitor binds in the active site cleft in a substrate-like manner, can be processed by MT-SP1 at low pH, and is a standard mechanism inhibitor of the protease. The mechanisms of inhibition provide a rationale for the effectiveness of these inhibitors, and suggest that the development of specific antibody-based inhibitors against individual members of closely related enzyme families is feasible, and an effective way to develop tools to tease apart complex biological processes.
- Published
- 2007
32. Phosphorylation Meets Proteolysis
- Author
-
Martin Renatus and Christopher J. Farady
- Subjects
chemistry.chemical_classification ,Proteases ,Protease ,medicine.diagnostic_test ,biology ,Chemistry ,medicine.medical_treatment ,Proteolysis ,Article ,Deubiquitinating enzyme ,Enzyme ,Biochemistry ,Structural Biology ,medicine ,biology.protein ,Phosphorylation ,Molecular Biology - Abstract
Caspases, a family of apoptotic proteases, are increasingly recognized as being extensively phosphorylated, usually leading to inactivation. To date, no structural mechanism for phosphorylation-based caspase inactivation is available, although this information may be key to achieving caspase-specific inhibition. Caspase-6 has recently been implicated in neurodegenerative conditions including Huntington's and Alzheimer's diseases. A full understanding of caspase-6 regulation is crucial to caspase-6-specific inhibition. Caspase-6 is phosphorylated by ARK5 kinase at serine 257 leading to suppression of cell death via caspase-6 inhibition. Our structure of the fully inactive phosphomimetic S257D reveals that phosphorylation results in a steric clash with P201 in the L2′ loop. Removal of the proline side chain alleviates the clash resulting in nearly wild-type activity levels. This phosphomimetic-mediated steric clash causes misalignment of the substrate-binding groove, preventing substrate binding. Substrate-binding loop misalignment appears to be a widely used regulatory strategy among caspases and may present a new paradigm for caspase-specific control.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.